Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder

por Michaelson, M D, Shipley, W U, Heney, N M, Zietman, A L, Kaufman, D S
Publicado 2004

Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma

por Cella, D, Bushmakin, A G, Cappelleri, J C, Charbonneau, C, Michaelson, M D, Motzer, R J
Publicado 2012

Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α

por Patil, S, Figlin, R A, Hutson, T E, Michaelson, M D, Negrier, S, Kim, S T, Huang, X, Motzer, R J
Publicado 2012

Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-α in a phase III trial: final results and geographical analysis...

por Cella, D, Michaelson, M D, Bushmakin, A G, Cappelleri, J C, Charbonneau, C, Kim, S T, Li, J Z, Motzer, R J
Publicado 2010

Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study

por Michaelson, M D, Zhu, A X, Ryan, D P, McDermott, D F, Shapiro, G I, Tye, L, Chen, I, Stephenson, P, Patyna, S, Ruiz-Garcia, A, Schwarzberg, A B
Publicado 2013

Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma

por Lee, Chung-Han, Motzer, Robert J., Glen, Hilary, Michaelson, M. D., Larkin, James, Minoshima, Yukinori, Kanekiyo, Michio, Ikezawa, Hiroki, Sachdev, Pallavi, Dutcus, Corina E., Funahashi, Yasuhiro, Voss, Martin H.
Publicado 2020

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

por Escudier, B, Michaelson, M D, Motzer, R J, Hutson, T E, Clark, J I, Lim, H Y, Porfiri, E, Zalewski, P, Kannourakis, G, Staehler, M, Tarazi, J, Rosbrook, B, Cisar, L, Hariharan, S, Kim, S, Rini, B I
Publicado 2014